All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.
The MDS Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MDS Hub cannot guarantee the accuracy of translated content. The MDS Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
During the 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (Tandem Meetings), the MDS Hub was pleased to speak with Charles Craddock, Queen Elizabeth Hospital Birmingham, Birmingham, UK. We asked, What does the FIGARO trial reveal about predictors of outcome post-transplant?
What does the FIGARO trial reveal about predictors of outcome post-transplant?
Craddock begins by outlining the trial aims and design, which investigated the use of the FLAMSA-Bu conditioning regimen in adult patients with AML. Craddock outlines the study results, noting that the presence of pretransplant measurable residual disease (MRD) is still associated with increased risk of relapse, and the most important predictor of outcome. Finally, Craddock discusses full donor T-cell chimerism, and reduced intensity conditioning (RIC) allograft strategies and mechanisms.
Subscribe to get the best content related to MDS delivered to your inbox